HLVX Stock Price, HilleVax, Inc. Quote, Chart

Market Summary

USD14.02+0.46

Market Closed

3.39%

HLVX Alerts

2 major insider buys recently.

HLVX Stock Price

View Fullscreen

HLVX RSI Chart

HLVX Valuation

Market Cap

696.8M

Price/Earnings (Trailing)

-5.64

Price/Free Cashflow

-7.14

HLVX Price/Earnings (Trailing)

HLVX Profitability

Return on Equity

-46.54%

Return on Assets

-35.88%

Free Cashflow Yield

-14%

HLVX Fundamentals

HLVX Earnings

Earnings (TTM)

-123.6M

Earnings Growth (Yr)

-74.44%

Earnings Growth (Qtr)

-16.17%

Breaking Down HLVX Revenue

Last 7 days

16.6%

Last 30 days

-10.4%

Last 90 days

-3.3%

Trailing 12 Months

0.8%

How does HLVX drawdown profile look like?

HLVX Financial Health

Current Ratio

10.62

Debt/Equity

0.1

Debt/Cashflow

-3.44

HLVX Investor Care

Shares Dilution (1Y)

26.62%

Diluted EPS (TTM)

-3.04

Tracking the Latest Insider Buys and Sells of HilleVax, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2024	kohli aditya	sold	-86,640	14.44	-6,000	-
Apr 04, 2024	frazier life sciences x, l.p.	bought	128,325	14.5	8,850	-
Apr 04, 2024	kohli aditya	sold	-88,245	14.7075	-6,000	-
Apr 03, 2024	kohli aditya	sold	-89,581	14.9303	-6,000	-
Mar 28, 2024	mcloughlin sean	bought	21,225	16.98	1,250	chief operating officer
Mar 20, 2024	kohli aditya	sold	-985,326,000	164,221	-6,000	-
Mar 19, 2024	kohli aditya	sold	-104,492	17.4153	-6,000	-
Mar 18, 2024	kohli aditya	sold	-105,937	17.6561	-6,000	-
Mar 08, 2024	kohli aditya	sold	-111,959	18.6598	-6,000	-
Mar 07, 2024	kohli aditya	sold	-110,213	18.3688	-6,000	-

Which funds bought or sold HLVX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	66.00	66.00	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-5.68	-26,822	1,155,040	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-55.45	-17,000	15,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	added	24.47	75,491	231,040	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	26.95	7,991,170	23,510,700	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	134	418,561	652,080	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	23.00	66,659	209,148	-%
Feb 15, 2024	Legal & General Group Plc	added	4.2	32,445	165,748	-%

Are Funds Buying or Selling HLVX?

Are funds buying HLVX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HLVX

No. of Funds

HLVX Alerts

2 major insider buys recently.

Unveiling HilleVax, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ra capital management, l.p.	0%	0	SC 13G/A
Feb 14, 2024	lightspeed venture partners select iv, l.p.	4.8%	2,303,871	SC 13G/A
Feb 14, 2024	deep track capital, lp	5.99%	2,900,000	SC 13G/A
Feb 12, 2024	flynn james e	4.38%	2,121,577	SC 13G/A
Feb 12, 2024	carlyle group inc.	3.8%	1,838,486	SC 13G/A
Sep 29, 2023	deep track capital, lp	6.14%	2,900,000	SC 13G
Sep 27, 2023	frazier life sciences public fund, l.p.	2.6%	1,246,135	SC 13D/A
May 05, 2023	frazier life sciences public fund, l.p.	3.2%	1,246,135	SC 13D/A
Feb 14, 2023	ra capital management, l.p.	5.3%	1,760,019	SC 13G
Feb 10, 2023	flynn james e	2.43%	811,447	SC 13G/A

Recent SEC filings of HilleVax, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 12, 2024	PRE 14A	PRE 14A
Apr 08, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 20, 2024	10-K	Annual Report
Mar 20, 2024	144	Notice of Insider Sale Intent
Mar 20, 2024	4	Insider Trading

HilleVax, Inc. News

Latest updates

HilleVax, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet									(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-6.1%	344	367	287	301	317	322	341	115	127
Current Assets	-6.8%	311	333	253	270	291	300	320	112	125
Cash Equivalents	3.9%	217	209	158	261	279	292	315	111	125
Net PPE	2.0%	14.00	14.00	13.00	10.00	6.00	1.00	-	-	0.00
Liabilities	15.5%	79.00	68.00	68.00	58.00	50.00	35.00	38.00	283	228
Current Liabilities	54.4%	29.00	19.00	18.00	19.00	13.00	9.00	13.00	283	228
Long Term Debt	0.8%	25.00	25.00	25.00	15.00	15.00	5.00	5.00	-	-
LT Debt, Non Current	0.8%	25.00	25.00	25.00	15.00	15.00	5.00	5.00	-	-
Shareholder's Equity	-11.1%	266	299	219	243	267	287	303	-	-100
Retained Earnings	-10.5%	-388	-351	-319	-291	-264	-243	-227	-173	-105
Additional Paid-In Capital	0.7%	655	651	539	535	532	531	530	5.00	4.00
Shares Outstanding	0.5%	48.00	47.00	38.00	38.00	38.00	24.00	27.00	7.00	7.00
Float	-	-	-	258	-	-	-	228	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)												(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Cashflow From Operations	19.4%	-21,606	-26,806	-22,417	-15,954	-18,517	-19,547	-13,210	-10,715	-4,194	-1,565	-1,119	-417
Share Based Compensation	-4.8%	3,756	3,946	3,246	2,642	1,331	844	556	272	-	-	-	-
Cashflow From Investing	194.5%	29,469	-31,174	-89,948	-2,985	-3,829	-185	-	-2,500	-	-	-	-
Cashflow From Financing	-99.7%	313	108,107	10,198	80.00	9,687	-2,820	218,201	-99.00	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HLVX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development (includes related party amounts of $362 and $2,426, respectively)	$ 106,683	$ 45,908
In-process research and development - related party		2,500
General and administrative (includes related party amounts of $0 and $40, respectively)	26,662	16,705
Total operating expenses	133,345	65,113
Loss from operations	(133,345)	(65,113)
Other income (expense):
Interest income	9,706	3,875
Interest expense (includes related party amounts of $0 and $717, respectively)	(2,392)	(3,414)
Change in fair value of convertible promissory notes (includes related party amounts of $0 and $13,196, respectively)		(51,469)
Change in fair value of warrant liabilities - related party		(43,575)
Other income (expense)	2,465	(113)
Total other income (expense)	9,779	(94,696)
Net loss	(123,566)	(159,809)
Other comprehensive loss:
Pension and other postemployment benefits	(620)	(281)
Unrealized loss on marketable securities	(6)
Total comprehensive loss	$ (124,192)	$ (160,090)
Net loss per share, basic	$ (3.04)	$ (5.89)
Net loss per share, diluted	$ (3.04)	$ (5.89)
Weighted-average shares of common stock outstanding, basic	40,598,482	27,147,314
Weighted-average shares of common stock outstanding, diluted	40,598,482	27,147,314

HLVX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 216,678	$ 279,401
Marketable securities	86,805
Prepaid expenses and other current assets	7,195	11,212
Total current assets	310,678	290,613
Property and equipment, net	14,018	5,586
Operating lease right-of-use assets	18,082	19,359
Restricted cash	1,631	1,631
Other assets	25	22
Total assets	344,434	317,211
Current liabilities:
Accounts payable (includes related party amounts of $0 and $141, respectively)	7,461	4,744
Accrued expenses (includes related party amounts of $33 and $140, respectively)	18,553	8,210
Accrued interest	134	55
Current portion of operating lease liability	3,118	37
Total current liabilities	29,266	13,046
Operating lease liability, net of current portion	22,831	21,569
Long-term debt, net of debt discount	25,244	14,792
Other long-term liabilities	1,568	575
Total liabilities	78,909	49,982
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.0001 par value; authorized shares - 50,000,000 at December 31, 2023 and December 31, 2022; no shares issued and outstanding at December 31, 2023 and December 31, 2022
Common stock, $0.0001 par value; authorized shares - 500,000,000 at December 31, 2023 and December 31, 2022; issued shares - 48,497,853 and 39,240,746 at December 31, 2023 and December 31, 2022, respectively; outstanding shares - 47,666,438 and 37,656,037 at December 31, 2023 and December 31, 2022, respectively	5	4
Additional paid-in capital	654,986	532,499
Accumulated other comprehensive loss	(907)	(281)
Accumulated deficit	(388,559)	(264,993)
Total stockholders' equity	265,525	267,229
Total liabilities and stockholders' equity	$ 344,434	$ 317,211

About HilleVax, Inc.

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

CEO	Dr. Robert M. Hershberg M.D., Ph.D.
WEBSITE	hillevax.com
INDUSTRY	Biotechnology
EMPLOYEES	62

HilleVax, Inc. Frequently Asked Questions

What is the ticker symbol for HilleVax, Inc.? What does HLVX stand for in stocks?

HLVX is the stock ticker symbol of HilleVax, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of HilleVax, Inc. (HLVX)?

As of Thu May 02 2024, market cap of HilleVax, Inc. is 696.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HLVX stock?

You can check HLVX's fair value in chart for subscribers.

What is the fair value of HLVX stock?

You can check HLVX's fair value in chart for subscribers. The fair value of HilleVax, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of HilleVax, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HLVX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is HilleVax, Inc. a good stock to buy?

The fair value guage provides a quick view whether HLVX is over valued or under valued. Whether HilleVax, Inc. is cheap or expensive depends on the assumptions which impact HilleVax, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HLVX.